TARGRETINCopy

• DRUGBANK - Bexarotene
• indication:

  Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.

• pharmacology:

• mechanism:

  Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR<sub>α</sub>, RXR<sub>β</sub>, RXR<sub>γ</sub>. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.

• toxicity:

• absorprion:

• halflife:

  7 hours

• roouteelimination:

  Urinary elimination of bexarotene and its known metabolites is a minor excretory pathway (<1% of administered dose).

• volumedistribution:

• clearance: